---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-093314"
form_type: "8-K"
ticker: "CGEM"
cik: "0001789972"
company_name: "Cullinan Therapeutics, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:07:47.876221+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cullinan Q2 net loss $42M; cash $664.9M; advancing CLN-978 IND in SLE for Q3 2024

## Summary
- Net loss $42.0M vs $32.2M Q2 2023; R&D $36.3M, G&A $13.8M; cash runway into 2028.
- CLN-978 (CD19xCD3 T cell engager) IND for SLE on track for Q3 2024; pursuing RA with FAU Erlangen & Università Cattolica.
- CLN-619 combo data at ASCO showed objective responses in oncogenic mutation NSCLC; expansion cohorts added.
- Positive initial zipalertinib data from REZILIENT1 study; ESMO presentation planned.
- Discontinued CLN-418; returned rights to Harbour BioMed. Oversubscribed PIPE raised $280M in April.

## SEC filing metadata
- accession: 0000950170-24-093314
- form_type: 8-K
- ticker: CGEM
- cik: 0001789972
- company_name: Cullinan Therapeutics, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789972/000095017024093314/0000950170-24-093314-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789972/000095017024093314/cgem-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-093314
- JSON: https://secwatch.observer/filing/0000950170-24-093314.json
- Plain text: https://secwatch.observer/filing/0000950170-24-093314.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.